264 related articles for article (PubMed ID: 17565157)
1. Prostate cancer progression and survival in BRCA2 mutation carriers.
Tryggvadóttir L; Vidarsdóttir L; Thorgeirsson T; Jonasson JG; Olafsdóttir EJ; Olafsdóttir GH; Rafnar T; Thorlacius S; Jonsson E; Eyfjord JE; Tulinius H
J Natl Cancer Inst; 2007 Jun; 99(12):929-35. PubMed ID: 17565157
[TBL] [Abstract][Full Text] [Related]
2. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000.
Tryggvadottir L; Sigvaldason H; Olafsdottir GH; Jonasson JG; Jonsson T; Tulinius H; Eyfjörd JE
J Natl Cancer Inst; 2006 Jan; 98(2):116-22. PubMed ID: 16418514
[TBL] [Abstract][Full Text] [Related]
3. BRCA2 mutation carriers, reproductive factors and breast cancer risk.
Tryggvadottir L; Olafsdottir EJ; Gudlaugsdottir S; Thorlacius S; Jonasson JG; Tulinius H; Eyfjord JE
Breast Cancer Res; 2003; 5(5):R121-8. PubMed ID: 12927042
[TBL] [Abstract][Full Text] [Related]
4. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
5. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
6. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S
J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636
[TBL] [Abstract][Full Text] [Related]
7. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
[TBL] [Abstract][Full Text] [Related]
8. Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic.
Horsburgh S; Matthew A; Bristow R; Trachtenberg J
Prostate; 2005 Oct; 65(2):124-9. PubMed ID: 15880530
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
Soegaard M; Kjaer SK; Cox M; Wozniak E; Høgdall E; Høgdall C; Blaakaer J; Jacobs IJ; Gayther SA; Ramus SJ
Clin Cancer Res; 2008 Jun; 14(12):3761-7. PubMed ID: 18559594
[TBL] [Abstract][Full Text] [Related]
10. Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families.
Thorne H; Willems AJ; Niedermayr E; Hoh IM; Li J; Clouston D; Mitchell G; Fox S; Hopper JL; ; Bolton D
Cancer Prev Res (Phila); 2011 Jul; 4(7):1002-10. PubMed ID: 21733824
[TBL] [Abstract][Full Text] [Related]
11. Tumour diploidy and survival in breast cancer patients with BRCA2 mutations.
Tryggvadottir L; Olafsdottir EJ; Olafsdottir GH; Sigurdsson H; Johannsson OT; Bjorgvinsson E; Alexiusdottir K; Stefansson OA; Agnarsson BA; Narod SA; Eyfjord JE; Jonasson JG
Breast Cancer Res Treat; 2013 Jul; 140(2):375-84. PubMed ID: 23857704
[TBL] [Abstract][Full Text] [Related]
12. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer as a second primary in patients with prostate cancer--estrogen treatment or association with family history of cancer?
Karlsson CT; Malmer B; Wiklund F; Grönberg H
J Urol; 2006 Aug; 176(2):538-43. PubMed ID: 16813884
[TBL] [Abstract][Full Text] [Related]
14. Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families.
Barkardottir RB; Sarantaus L; Arason A; Vehmanen P; Bendahl PO; Kainu T; Syrjäkoski K; Krahe R; Huusko P; Pyrhönen S; Holli K; Kallioniemi OP; Egilsson V; Kere J; Nevanlinna H
Eur J Hum Genet; 2001 Oct; 9(10):773-9. PubMed ID: 11781689
[TBL] [Abstract][Full Text] [Related]
15. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men.
Gong Z; Agalliu I; Lin DW; Stanford JL; Kristal AR
Cancer; 2007 Mar; 109(6):1192-202. PubMed ID: 17311344
[TBL] [Abstract][Full Text] [Related]
16. Segregation analysis of 389 Icelandic pedigrees with Breast and prostate cancer.
Baffoe-Bonnie AB; Kiemeney LA; Beaty TH; Bailey-Wilson JE; Schnell AH; Sigvaldason H; Olafsdóttir G; Tryggvadóttir L; Tulinius H
Genet Epidemiol; 2002 Nov; 23(4):349-63. PubMed ID: 12432503
[TBL] [Abstract][Full Text] [Related]
17. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
[TBL] [Abstract][Full Text] [Related]
18. Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.
Willems AJ; Dawson SJ; Samaratunga H; De Luca A; Antill YC; Hopper JL; Thorne HJ;
Clin Cancer Res; 2008 May; 14(10):2953-61. PubMed ID: 18445692
[TBL] [Abstract][Full Text] [Related]
19. Hereditary breast/ovarian cancer: clinicopathological characteristics and survival of BRCA2 positive and negative cases.
Syamala V; Syamala VS; Sreeja L; Raveendran PB; Vijayalekshmi RV; Sheeja VR; Santhi S; Kuttan R; Abraham EK; Ankathil R
J Exp Ther Oncol; 2008; 7(3):227-36. PubMed ID: 19066131
[TBL] [Abstract][Full Text] [Related]
20. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
Gallagher DJ; Gaudet MM; Pal P; Kirchhoff T; Balistreri L; Vora K; Bhatia J; Stadler Z; Fine SW; Reuter V; Zelefsky M; Morris MJ; Scher HI; Klein RJ; Norton L; Eastham JA; Scardino PT; Robson ME; Offit K
Clin Cancer Res; 2010 Apr; 16(7):2115-21. PubMed ID: 20215531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
